Navigation Links
DNA2.0 Expands European Presence By Opening UK Office: Experienced Life Sciences Executive, Dr. Michael Dyson, to Lead European Operations

DNA2.0 opens DNA2.0 Ltd. in the United Kingdom and hires Michael Dyson to run European operations.

Menlo Park, CA (PRWEB) December 10, 2008 -- DNA2.0, the leading gene synthesis and protein engineering company, today announced the expansion of the company's European operations with the creation of the United Kingdom-based DNA2.0 Ltd. Michael Dyson, PhD, has been appointed as Managing Director of European Operations and will lead the new venture in the UK as well as DNA2.0's established office in Basel, Switzerland.

"The opening of our UK headquarters represents a major step in our global growth," said Jeremy Minshull, President of DNA2.0. "Even in a time of economic uncertainty, the market for gene synthesis and its many applications continues to grow rapidly in Europe. We are confident that European customers will continue to seek out our world-class customer support, fast and reliable turnaround time and the certainty that their intellectual property is completely protected."

While many other gene synthesis companies offshore manufacturing to areas of the world with lax IP protection, all DNA2.0 genes are made at the company's state-of-the-art facility in Menlo Park, thus ensuring the greatest security for patented or confidential sequences. DNA2.0's two European locations ensure that European customers receive the same PhD-level service and support as their U.S. counterparts.

"The demand in the European marketplace for high quality synthetic genes, delivered quickly and with confidence, is tremendous," said Dr. Dyson. "We look forward to serving our European customers even more effectively through this new base of operations."

Dr. Dyson possesses more than 20 years of experience leading European customer service and sales organizations in the life sciences industry. He has particular experience growing and managing life science businesses across Europe, and prior to joining DNA2.0 he was European Managing Director for Codon Devices. He has also held chief management positions at such life science companies as Sequenom, MicroCal and PerSeptive Biosystems.

About DNA2.0:
Founded in early 2003, DNA2.0 is the leading synthetic genomics company. It is the fastest provider of synthetic genes, based in the US with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 has provided genes to thousands of customers, for whom it has synthesized many millions of base pairs. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly efficient gene synthesis process and new protein optimization technologies. The tools and applications brought to market by DNA2.0 are transforming biology into an engineering discipline. The company is privately held and is headquartered in Menlo Park, Calif. For more information, please visit


Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
2. Rohm and Haas Expands in India
3. Concentra Expands Horizon Air Employee Health Program With On-Site Clinic
4. Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs
5. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors
6. Specialty Blades, Inc. Expands Management Team With New VP Engineering
7. CRH Medical expands Las Vegas operations
8. US Med-Equip Expands Corporate Support Center
9. ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments
10. Bipartisan Bill Expands Health Care Access for Small Businesses
11. ABR-Affinity BioReagents Expands 100% Quality Guarantee
Post Your Comments:
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: